European Journal of Molecular & Clinical Medicine

Background: Platelets play a vital role in hemostasis. Idiopathic / Immune
thrombocytopenic purpura (ITP) is a common bleeding disorder in children, where
autoantibodies mediated consumption of the platelets, suppression of platelet
production by bone marrow megakaryocytes leads to thrombocytopenia and bleeding
manifestations. Incidence is 6.4 per 10000 among children and 3.3 per 10000 adults per
year.1 There is highest male to female ratio in infancy and it decreases with older age
groupchildren. No significant seasonal variation. Vaccination may play an important
role in the etiology of ITP in infants. History of a preceding viral infection 1-6 weeks
before the onset disease is present in 60% of cases. Bone. narrow was routinely
performed but evidences confirmedthat its rarely needed at presentation, must be
considered if having severe bleeding or not responding to treatment.
Materials &Methods:Details about children with ITP who presented to our hospital
between October 2020 and August 2021 were collected using a proforma. The study was
designed as a cross-sectional study. To meet the sample size, convenience sampling was
used.
Results: Total number of children recruited with a clinical diagnosis of primary itp was
120 after excluding the ones which had a secondary cause identified, the total primary
itp studied were 100. among them based on the duration of symptoms (as per
definitions) they were categorized into newly diagnosed, persistent and chronic itp.
There were 46 cases of chronic itp and 44 cases of persistent ITP. 73 percent of all
patients were between the ages of 1 and 10 years. in total, 8.9 percent of them had severe
bleeds. there was no link discovered between bleeding and platelet count. a high nordic
score (10-14) had a high predictability for short-term symptoms.
Conclusion: In our study, there was a higher incidence of its presenting in the hospital.
Higher a percentage of them had severe bleeding.

Immune thrombocytopenia or ITP is an autoimmune disorder in which the body creates autoantibodies against its thrombocytes or platelets that are destroyed, resulting in purpura or minor bleeding spots under the surface. It is most often found in cancer patients and is of growing concern.While the main causes of thrombocytopenia in cancer pat ients are chemotherapy and radiation, other aetiologies should also be considered in patients suffering
 from this debilitating disease. Thrombocytopenia causes a variety of complications in the treatment of cancer patients and therefore pharmacists need to be familiar with epidemiology, pathophysiology, risk factors, diagnostic methods, and emerging therapeutic options for chronic immune thrombocytopenia to help oncologists identify and implement realistic treatment measures for chronic immune thrombocytopenia patients undergoing cancer treatment.The objective of this review is to provide a brief overview of chronic immune thrombocytopenia and various strategies for the clinical management of the disease.